MAPKAPK2 and neoplasm: Although MK2 depletion clearly enhanced tumor cell responses to cisplatin (Fig. 3i–m; Supplementary Fig. 6D, E), the overall increase in survival was modest (Fig. 3n; Supplementary Fig. 6F).